What is Neuronoff?
Neuronoff is a pioneering medical technology firm dedicated to transforming the landscape of pain management through its proprietary Injectrode platform. The company addresses the limitations of traditional, invasive surgical procedures and long-term pharmaceutical reliance by utilizing a needle-based delivery system. This innovative approach creates a low-impedance path for electrical signals, effectively modulating nerve activity to provide sustained relief for patients suffering from chronic pain conditions.
By prioritizing a minimally invasive methodology, Neuronoff is effectively lowering the barrier to entry for advanced neuromodulation therapies. The company's market position is defined by its ability to bridge the gap between complex neuro-stimulation research and accessible, patient-centric clinical applications. This strategic focus on reducing surgical complexity while maintaining high therapeutic efficacy positions Neuronoff as a disruptive force within the broader healthcare technology sector.
How much funding has Neuronoff raised?
Neuronoff has raised a total of $12.2M across 3 funding rounds:
Multiple Rounds
$12.2M
Grant (2025): $3.2M with participation from National Institutes of Health
Other Financing Round (2025): $4.5M, investors not publicly disclosed
Other Financing Round (2025): $4.5M, investors not publicly disclosed
Key Investors in Neuronoff
National Institutes of Health
The National Institutes of Health is the primary agency of the United States government responsible for biomedical and health-related research, providing critical grant support for innovative medical breakthroughs.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Neuronoff?
With the recent completion of its latest financing round, Neuronoff is well-positioned to advance its clinical development pipeline and expand its regulatory footprint. The strategic allocation of these funds will likely focus on scaling manufacturing processes for the Injectrode system and initiating broader clinical trials to solidify the platform's efficacy profile. As the company moves toward wider market adoption, the focus will shift from foundational research to commercial scalability and strategic partnerships with healthcare providers.
The long-term outlook for Neuronoff remains centered on establishing the Injectrode as a standard-of-care alternative to opioid-based pain management. By leveraging its recent capital injection, the firm is poised to navigate the complexities of the medical device regulatory environment while simultaneously building the infrastructure necessary to support a national, and eventually global, rollout of its pain management solutions.
